Development and in vitro evaluation of doxorubicin and celecoxib co-loaded bone targeted nanoparticles

Kozlu, Serhat; Sahin, Adem; Ultav, Gozde; Yerlikaya, Firat; Çalış, Sema; Çapan, Yılmaz

doi:10.1016/j.jddst.2018.02.004

Cited by 8 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was used for the second part of the study. DOX is an anthracycline antibiotic, which, at the molecular level, interacts with DNA and interferes with nucleic acid synthesis, resulting in a remarkable effect on DNA transcription [40,41].…”

Section: Discussionmentioning

confidence: 99%

Magnetic Composite Scaffolds for Potential Applications in Radiochemotherapy of Malignant Bone Tumors

et al. 2019

View full text Add to dashboard Cite

Background and objectives: Cancer is the second leading cause of death globally, an alarming but expected increase. In comparison to other types of cancer, malignant bone tumors are unusual and their treatment is a real challenge. This paper’s main purpose is the study of the potential application of composite scaffolds based on biopolymers and calcium phosphates with the inclusion of magnetic nanoparticles in combination therapy for malignant bone tumors. Materials and Methods: The first step was to investigate if X-rays could modify the scaffolds’ properties. In vitro degradation of the scaffolds exposed to X-rays was analyzed, as well as their interaction with phosphate buffer solutions and cells. The second step was to load an anti-tumoral drug (doxorubicin) and to study in vitro drug release and its interaction with cells. The chemical structure of the scaffolds and their morphology were studied. Results: Analyses showed that X-ray irradiation did not influence the scaffolds’ features. Doxorubicin release was gradual and its interaction with cells showed cytotoxic effects on cells after 72 h of direct contact. Conclusions: The obtained scaffolds could be considered in further studies regarding combination therapy for malignant bone tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Magnetic Composite Scaffolds for Potential Applications in Radiochemotherapy of Malignant Bone Tumors

et al. 2019

View full text Add to dashboard Cite

show abstract

“…To probe the drug-release properties of the PCL/HA composites, Doxorubicin (DOX) were chosen as a model drug and mixed in the samples. DOX is a chemotherapy drug that is used to inhibit the growth of tumors cells [26][27][28][29]. In this work, 10 mg of DOX is mixed with each 100 mg of the pure PCL or PCL/HA composite sample.…”

Section: In Vitro Drug-release Property Of Pcl/ha Scaffoldsmentioning

confidence: 99%

“…Recent studies show that the release amount of DOX at rst 100 h could reach over 80% [29,30], such high release rate could inhabit the regeneration of new bone tissue in the tissue engineering. Thus, a controllable release rate is a necessity.…”

Section: In Vitro Drug-release Property Of Pcl/ha Scaffoldsmentioning

confidence: 99%

3D printed multi-functional scaffolds based on poly(ε-caprolactone) and hydroxyapatite composite

Liu

Kang

Liu

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Biodegradable polymeric scaffolds are critical to repair a large bone defect, which can provide a porous and network microenvironment for cell attachment and bone tissue regeneration. A multifunctional biodegradable PCL/HA composite was prepared with the blending of poly(ε-caprolactone) (PCL) and hydroxyapatite nanoparticles (HA). Subsequently, the PCL/HA scaffolds implants were produced by the screw extrusion/melting deposition forming method using PCL/HA composite as a raw material in this work. Results: Through a serial of in vitro assessments, it is found that the PCL/HA composite possesses good biodegradability, good biocompatibility, and steady drug release performance, which can improve the cell proliferation of osteoblast cells MC3T3-E1. Meanwhile, in vivo experiments were carried out for the rats with skull defect and rabbits with bone defects. It is observed that the PCL/HA scaffolds implants allow the adhesion and penetration of bone cells, which enables the growth of bone cells and bone tissue regeneration. With a composite design to load an anticancer drug and achieve sustained drug release, the scaffolds could enhance bone repair and be expected to inhibit the tumor cells and improve patient outcomes. Conclusions: This work signifies that PCL/HA composite can be used as the potential biodegradable scaffolds for bone repairing after bone malignant tumor resection.

show abstract

“…PTX is one of the most effective chemotherapeutic agents with extensive activity against cancers in humans and it can induce the apoptosis of cancer cells [31]. Flow cytometry was adopted to verify whether HA-Se@PTX could trigger A549 cells apoptosis.…”

Section: Ha-se@ptx Trigger A549 Cell Apoptosismentioning

confidence: 99%

Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy

Zou

Chen

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Targeted delivery of chemotherapeutics by functionalized nanoparticles exhibits a wonderful prospect for cancer treatment. In this paper, selenium nanoparticles (SeNPs) was linked with hyaluronic acid (HA) to prepare tumor-targeted delivery vehicle HA-SeNPs, and HA-SeNPs was loaded with paclitaxel (PTX) to fabricate functionalized selenium nanoparticles HA-Se@PTX. HA-Se@PTX showed greater uptake in A549 cells in comparison with that in HUVEC, verifying HA-mediated specific uptake of HA-Se@PTX. HA-Se@PTX was capable of entering A549 cells via clathrin-associated endocytosis and showed faster drug release in cancer cell microenvironment in comparison with normal physiological environment. HA-Se@PTX could obviously inhibit the proliferation, migration and invasion of A549 cells and trigger A549 cells apoptosis. Moreover, active targeting functionalized selenium nanoparticles HA-Se@PTX showed greater in vivo antitumor activity compared with free PTX or passive targeting delivery system Se@PTX. In addition, HA-Se@PTX exhibited negligible toxicity on the major organs of mice. In a word, HA-Se@PTX may develop into a valuable nanoscale antitumor drug agent for lung cancer treatment.

show abstract

Development and in vitro evaluation of doxorubicin and celecoxib co-loaded bone targeted nanoparticles

Cited by 8 publications

References 26 publications

Magnetic Composite Scaffolds for Potential Applications in Radiochemotherapy of Malignant Bone Tumors

Magnetic Composite Scaffolds for Potential Applications in Radiochemotherapy of Malignant Bone Tumors

3D printed multi-functional scaffolds based on poly(ε-caprolactone) and hydroxyapatite composite

Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy

Contact Info

Product

Resources

About